ANN ARBOR, MICHIGAN, Sept 24, 2018 — Genomenon, Inc. has been selected as a 2018 TiE20 Winner for the prestigious TiE20 Awards Program. The company has been recognized for its work in Next Generation Sequencing (NGS) interpretation with theMastermind Genomic Search Engine. Mastermind assists doctors and researchers in connecting patient DNA with the most relevant medical research. The competition is a part of TiECon Detroit 2018, Michigan’s largest conference for entrepreneurs.
“It’s an honor to be selected among this elite list of entrepreneurs and companies by TiE20for our leadership in applying artificial intelligence (AI) to the field of genomic interpretation,” said Mike Klein, CEO, Genomenon, Inc.
TiE20 has become a global brand that attracts thousands of companies worldwide. Selected from more than 500 nominated companies, the winners represent the most enterprising startup companies in five focus segments: Sensors/Electronics/IOT, Food/Health/Fitness, Fintech, Blockchain/AI/ML/DL and Manufacturing/In Vehicle Technologies/Mobility. TiE20 winners will present their companies to the conference attendees. They will get special invitations to premium networking sessions at TiECon and will also be part of ongoing recognition from TiE Detroit throughout the year. More importantly, they will get access toTiE’s powerful global entrepreneurial ecosystem.
"TiE20 awards is where aspirations of today become an entrepreneurial reality of tomorrow. We are confident this is a first step towards identifying and to spotlight the next generation business creators in our region," said Tel K. Ganesan, President, TiE Detroit Chapter.
The TiE20 winners will be honored with awards of excellence at TiECon Detroit 2018 on Saturday, October 06, 2018, at 6:00 p.m at the Suburban Collection Showplace, 46100Grand River Ave, Novi, Michigan.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
